On June 29, 2022, the FDA announced its long-awaited guidelines on the timing of a second Evusheld dose.
Quoting from the FDA’s revised guidelines:
“Repeat dose: 300 mg of tixagevimab and 300 mg of cilgavimab (Evusheld) every 6 months. Repeat dosing should be timed from the date of the most recent EVUSHELD dose.”
That means if you were among the many who had a second “catch up” dose of Evusheld because your first dose was at the half strength of the now recommended dose, your next would be due six months after that last dose.
It was good news and early study results that led to this decision. “Nonclinical” data suggests that Evusheld continues to neutralize all the COVID-19 variants, including BA.4 and BA.5, for at least six months.
The timing of vaccine boosters and Evusheld is an area of much controversy, speculation, and very little data for the immunocompromised. Read more here about the most common questions surrounding booster doses and Evusheld.
CLL Society recommends everyone with CLL/SLL discuss with their doctors the role of Evusheld in their Pre-Exposure Prophylaxis (PrEP) of COVID-19. CLL Society believes it should be an option for all immunocompromised individuals, including those at any point in their CLL/SLL, regardless of their treatment status.
CLL Society has long been advocating for broader and better distribution of Evusheld. One of many examples is CLL Society Supports a Letter Written to the Department of Health and Human Services Regarding Evusheld Distribution.
Here’s the news from the FDA: FDA Authorizes Revisions to Evusheld Dosing.